Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-blind, Placebo-controlled Clinical Study Evaluating the Efficacy and Safety of JS002 in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia in China

Next Previous
X
Search
Trial Profile

A Phase III, Randomized, Double-blind, Placebo-controlled Clinical Study Evaluating the Efficacy and Safety of JS002 in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia in China

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ongericimab (Primary) ; HMG-CoA reductase inhibitors
  • Indications Hypercholesterolaemia; Hyperlipidaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Shanghai Junshi Biosciences

    • Most Recent Events

    • 25 Apr 2023 According to a Junshi Biosciences - Impact Therapeutics (JV) media release, the National Medical Products Administration has accepted the new drug application for JS002. new drug application is mainly based on three registered clinical trials (JS002-003, JS002-004 and JS002-006).
    • 27 Feb 2023 Results presented in the Junshi Biosciences Impact Therapeutics Media Release
    • 27 Feb 2023 Primary endpoint (LDL-C) has been met, according to a Junshi Biosciences Impact Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top